Wilmington Mesothelioma Prognosis: A Comprehensive Guide to Understanding Your Outlook
#Wilmington #Mesothelioma #Prognosis #Comprehensive #Guide #Understanding #Your #Outlook
Wilmington Mesothelioma Prognosis: A Comprehensive Guide to Understanding Your Outlook
Alright, let's talk about something incredibly tough, something that no one ever wants to hear discussed in the same breath as their name or the name of a loved one: mesothelioma. Specifically, we're going to delve deep into the prognosis for mesothelioma patients, with a particular eye on what this means for folks in and around Wilmington, North Carolina. And let me tell you, as someone who’s been around this field for a while, it's not a conversation to be taken lightly. It's complex, it's emotionally charged, and it requires a level of honesty that can sometimes feel brutal. But understanding is power, and when facing a diagnosis like this, every bit of power you can muster is absolutely vital.
We're not just going to skim the surface here. We're going to unpack what a prognosis truly signifies, moving beyond mere statistics to explore the nuances that shape an individual's journey. We’ll look at all the factors that doctors weigh, the treatments that offer a flicker of hope, and the realities of living with this aggressive disease. My goal here isn't to sugarcoat anything, but rather to empower you with knowledge, to help you ask the right questions, and to equip you for the long, challenging road ahead. Think of me as your seasoned guide, walking alongside you through this dense and often frightening forest of information.
What is Mesothelioma? A Brief Overview
Before we can even begin to talk about prognosis, we have to lay a foundational understanding of what mesothelioma is. Because honestly, for many, it's a word whispered in hushed tones, a vague, terrifying concept. But it's crucial to grasp its nature, its origins, and its insidious ways if we're to truly appreciate the complexities of its outlook. This isn't your run-of-the-mill cancer; it's a beast with a very specific, tragic lineage.
Defining Mesothelioma and its Causes
Mesothelioma is, in its simplest definition, a rare and aggressive cancer that develops from the thin layer of tissue that covers many of the internal organs. This tissue is called the mesothelium. When we talk about mesothelioma, we're almost always referring to malignant mesothelioma, a particularly nasty form of the disease. Now, here's the absolute, non-negotiable, singular truth about its cause: it is almost exclusively linked to asbestos exposure. There's no genetic predisposition in the vast majority of cases, no lifestyle choice, no dietary factor that causes it. It’s asbestos, pure and simple.
Think about that for a moment. This isn't a disease you "get." It's a disease that is given to you, often unknowingly, decades before symptoms ever emerge. Asbestos, that once-heralded "miracle mineral" used extensively in construction, shipbuilding, textiles, and countless industrial applications throughout the 20th century, is the villain here. When asbestos fibers are inhaled or ingested, they can become lodged in the mesothelium, causing irritation and inflammation over many, many years – sometimes 20, 30, even 50 years after the initial exposure. This long latency period is one of the cruelest aspects of mesothelioma, as it means people often don't realize they're sick until the disease is already quite advanced. For folks in places like Wilmington, with its rich maritime history and industrial past, the shadow of asbestos exposure looms large. Shipyards, power plants, older commercial buildings – these were all hotbeds of asbestos use, and the legacy of that exposure continues to manifest in diagnoses today. It’s a stark reminder of industrial negligence and the long-term human cost.
Types of Mesothelioma and Their Prevalence
While the term "mesothelioma" might sound monolithic, it actually manifests in several distinct forms, primarily differentiated by where the cancer originates in the body. Understanding these types is vital because each carries its own set of challenges and, yes, often a different prognostic outlook.
The most common form, by a significant margin, is pleural mesothelioma. This type develops in the pleura, the lining of the lungs and chest cavity. It accounts for about 75-80% of all mesothelioma cases. Symptoms often include shortness of breath, chest pain, and persistent cough, which, as you can imagine, can easily be mistaken for more benign respiratory issues, especially in the early stages. Its prevalence is directly tied to the inhalation of asbestos fibers, making it the primary concern for those with occupational exposure.
Next up, accounting for about 15-20% of cases, is peritoneal mesothelioma. This form develops in the peritoneum, the lining of the abdominal cavity. While less common, it's often associated with ingested asbestos fibers, though sometimes inhaled fibers can migrate to the abdomen. Symptoms here can be vague: abdominal pain, swelling, weight loss, and changes in bowel habits. These can be easily dismissed as digestive issues, again contributing to delayed diagnosis. However, historically, peritoneal mesothelioma has sometimes shown a slightly better response to certain aggressive treatments, particularly those involving heated chemotherapy directly applied to the abdomen, known as HIPEC.
Then we have the truly rare forms. Pericardial mesothelioma originates in the pericardium, the lining around the heart. This is exceedingly rare, making up less than 1% of cases. Its symptoms are often cardiac-related, such as chest pain, shortness of breath, and heart palpitations, making diagnosis incredibly challenging as it mimics more common heart conditions. The rarity of this type means that even specialist oncologists may have limited experience with it, underscoring the importance of seeking out true mesothelioma experts.
Finally, there's testicular mesothelioma, an even rarer form that develops in the tunica vaginalis, the lining of the testicles. This is so uncommon that it’s often diagnosed incidentally during surgery for other conditions. Its rarity means very little data exists on its specific prognosis, but generally, it's considered to have a somewhat better outlook than pleural mesothelioma, largely because it's often discovered at an earlier, more localized stage.
Understanding these distinctions isn't just academic; it directly influences the diagnostic pathway, the treatment strategies considered, and ultimately, the prognostic conversation you'll have with your medical team. Each type presents its own unique battleground.
Common Symptoms and Early Detection Challenges
Here's where the truly insidious nature of mesothelioma rears its ugly head: its symptoms are a masterclass in deception. They are vague, non-specific, and mimic a host of much more benign conditions. This, my friends, is why early diagnosis is not just rare, but tragically so, and why it becomes such a monumental hurdle in achieving a more favorable prognosis.
Let's take pleural mesothelioma, for instance. A persistent cough? Shortness of breath? Chest pain? Fatigue? These could be anything from a common cold or bronchitis to allergies, asthma, or even just being out of shape. How many times have you or someone you know brushed off a persistent cough, thinking it's just a lingering bug? Or attributed shortness of breath to getting older or carrying a few extra pounds? This is precisely the problem. The symptoms of mesothelioma typically don't become noticeable until the tumor has grown significantly, often spreading within the chest cavity, putting pressure on organs, and causing effusions (fluid buildup). By the time these symptoms become severe enough to warrant serious medical investigation, the disease is often already in an advanced stage.
For peritoneal mesothelioma, the story is much the same. Abdominal pain, bloating, weight loss, nausea, changes in bowel habits – these are symptoms that could easily be attributed to irritable bowel syndrome, indigestion, diverticulitis, or even just stress. I remember a patient, a wonderful woman from a small town near Wilmington, who spent months being treated for what doctors thought was a severe case of IBS before anyone even considered looking for something more sinister. Her frustration was palpable, and her eventual diagnosis was a devastating blow, not just because of the cancer, but because of the lost time.
This prolonged period of vague symptoms, often leading to misdiagnosis or delayed diagnosis, is a critical factor in the grim prognosis associated with mesothelioma. When the disease is caught in its earliest stages – something that almost never happens outside of incidental findings during unrelated surgeries – the options for aggressive, life-extending treatment are significantly better. But by the time the cough becomes unrelenting, or the abdominal swelling is undeniable, the window for curative-intent surgery may have already closed. That's why, if you have a history of asbestos exposure, even if it was decades ago, and you start experiencing any of these persistent, unexplained symptoms, you must advocate for yourself. Push for answers. Don’t let doctors dismiss your concerns, especially if you can provide that crucial piece of information about asbestos exposure. It could literally be the difference between a few months and a few years.
*
Pro-Tip: The Asbestos Connection is Key
If you or a loved one are experiencing persistent, unexplained symptoms – especially respiratory or abdominal issues – and have ANY history of asbestos exposure, no matter how brief or how long ago, bring this up immediately with your doctor. Do not wait. This information is a critical diagnostic clue that can fast-track investigations and potentially lead to an earlier diagnosis, which is paramount for prognosis. Wilmington's industrial past means many residents have this exposure history, often without realizing it.
*
Understanding Mesothelioma Prognosis: The Core Factors
Now that we’ve established what mesothelioma is and how difficult it is to catch early, let's dive into the meat of the matter: prognosis. This isn't just about statistics; it's about your future, your quality of life, and the potential pathways ahead. It's a deeply personal conversation, and understanding the factors that shape it is fundamental to navigating treatment decisions and setting realistic expectations.
What "Prognosis" Truly Means for Mesothelioma Patients
When a doctor talks about "prognosis," many people immediately jump to a single, often terrifying, number: survival rate. And while survival rates are undeniably a part of the prognostic picture, they are far from the whole story, especially with a disease as complex and aggressive as mesothelioma. For mesothelioma patients, prognosis is a multifaceted concept that encompasses much more than just how long someone might live.
Firstly, yes, it includes life expectancy or survival rates. These are typically expressed as median survival times (e.g., "median survival is 12-18 months") or as 1-year, 2-year, or 5-year survival rates (e.g., "the 5-year survival rate for this stage is X%"). These statistics are derived from large populations of patients and provide a general benchmark. But here's the critical caveat: you are not a statistic. These numbers don't account for individual biological variability, response to novel treatments, or the sheer willpower of a patient. They are averages, and every individual's journey can deviate significantly from the mean.
Secondly, prognosis absolutely includes quality of life. This is often overlooked in the initial shock of diagnosis, but it becomes incredibly important as treatment progresses. What good is extending life by a few months if those months are spent in unbearable pain, with severe side effects, and no ability to engage with loved ones or activities that bring joy? A good prognosis, in a holistic sense, aims not only to prolong life but also to preserve, or even improve, the patient's ability to live comfortably and meaningfully. This involves managing symptoms, mitigating treatment side effects, and supporting emotional and psychological well-being.
Thirdly, prognosis involves treatment response. Will the tumor shrink? Will its growth be halted? Will symptoms improve? A favorable prognostic indicator is a cancer that responds well to initial therapies, indicating that the chosen treatment path is having an impact. Conversely, a lack of response can signal the need to pivot quickly to alternative strategies.
Finally, prognosis is about outlook – a forward-looking assessment that considers all known factors to provide the patient and their family with a realistic understanding of the disease's likely course. It's an ongoing conversation, not a one-time pronouncement. As new information emerges – how a patient responds to a particular drug, the results of follow-up scans, or the development of new symptoms – the prognosis can and often does evolve. It's a dynamic assessment, and I always advise patients to view it as such, rather than a fixed sentence. It’s about understanding the likely path, but also acknowledging that individual experiences can, and often do, defy expectations.
Stage at Diagnosis: The Single Most Critical Factor
If you take one thing away from this entire discussion about prognosis, let it be this: the stage of mesothelioma at diagnosis is, without a shadow of a doubt, the single most critical factor influencing a patient's outlook. It dictates treatment options, significantly impacts life expectancy, and often determines whether curative-intent therapies are even on the table. It’s the harsh reality of this disease.
Mesothelioma, particularly pleural mesothelioma, is typically staged using systems like the Brigham, Butchart, or TNM (Tumor, Node, Metastasis) staging systems. While these systems have their nuances, they generally categorize the disease into four main stages, reflecting the extent of tumor growth and spread.
- Stage 1: This is the earliest stage, where the tumor is localized to one side of the chest (or abdomen for peritoneal) and has not spread to lymph nodes or distant organs. The tumor is typically confined to the lining itself. This is the stage where aggressive surgical interventions, often combined with chemotherapy and radiation, offer the best chance for long-term survival. Unfortunately, due to the insidious nature of symptoms, Stage 1 diagnoses are exceedingly rare, often discovered incidentally during unrelated medical procedures.
- Stage 2: The tumor has grown larger and may have spread to nearby lymph nodes on the same side of the chest, or into adjacent lung tissue or diaphragm. While still considered localized, the spread to lymph nodes indicates a more advanced disease. Surgical options may still be viable, but the complexity increases, and the prognosis begins to decline compared to Stage 1.
- Stage 3: At this stage, the cancer has spread more extensively within the chest cavity, potentially involving the chest wall, mediastinum (the area between the lungs), or other nearby structures, and may have spread to lymph nodes on both sides of the chest. It might also involve invasion of the diaphragm or peritoneum. Curative surgery becomes much more challenging, if not impossible, for many patients. Treatment often focuses on a multimodal approach combining chemotherapy, radiation, and sometimes palliative surgery to manage symptoms. The prognosis here is significantly reduced.
- Stage 4: This is the most advanced stage, characterized by distant metastasis – meaning the cancer has spread to distant organs, such as the brain, bones, or liver. At Stage 4, mesothelioma is considered systemic, and curative treatment is generally not an option. The focus shifts entirely to palliative care, aiming to control symptoms, improve quality of life, and extend life for as long as possible while minimizing suffering.
*
Insider Note: The Staging Paradox
It's a cruel paradox that the stage where mesothelioma is most treatable (Stage 1) is also the stage where it's almost never found. The symptoms are just too subtle. This highlights the need for vigilance, especially for individuals with known asbestos exposure history. Regular check-ups and open communication with your doctor about your exposure are your best defense, even if it feels like overkill.
*
Cell Type (Histology) and its Impact on Outlook
Beyond the stage of the disease, the specific type of cells that make up the tumor – known as histology – plays an incredibly significant role in determining a mesothelioma patient's prognosis. This isn't just a minor detail; it’s a fundamental biological characteristic of the cancer that dictates its behavior, its aggressiveness, and its responsiveness to various treatments.
There are three primary histological types of malignant mesothelioma:
- Epithelioid Mesothelioma: This is considered the "best" prognosis of the three types, though "best" is always a relative term when discussing mesothelioma. Epithelioid cells are cube-shaped and tend to grow in sheets or glandular patterns. They are generally less aggressive, spread more slowly, and are more responsive to treatment, particularly surgery and chemotherapy. Approximately 50-70% of all mesothelioma cases are epithelioid. Patients with this cell type often have a median survival that is significantly longer than those with other cell types, sometimes extending into several years with aggressive multimodal treatment. This cell type is generally more amenable to surgical resection and responds better to systemic therapies, offering a more hopeful, albeit still challenging, path forward.
- Sarcomatoid Mesothelioma: At the other end of the spectrum, we have sarcomatoid mesothelioma, which unfortunately carries the "worst" prognosis. These cells are spindle-shaped and resemble connective tissue cells, growing in a disorganized, invasive manner. Sarcomatoid tumors are highly aggressive, grow rapidly, and are notoriously resistant to most forms of treatment, including chemotherapy and radiation. They also tend to metastasize more quickly. This cell type accounts for about 10-20% of cases. Patients diagnosed with sarcomatoid mesothelioma typically face a much shorter median survival, often less than a year, even with aggressive interventions. The resistance to conventional therapies makes this a particularly challenging form to treat, often leading oncologists to explore clinical trials or more palliative approaches earlier in the treatment plan.
- Biphasic Mesothelioma: As the name suggests, biphasic mesothelioma is a mixture of both epithelioid and sarcomatoid cells. The prognosis for biphasic mesothelioma generally falls somewhere between epithelioid and sarcomatoid types. The exact outlook often depends on the predominant cell type within the tumor – if it's mostly epithelioid cells with a smaller component of sarcomatoid, the prognosis might lean more favorably. Conversely, if the sarcomatoid component is significant, the outlook will be more guarded. Biphasic mesothelioma accounts for about 20-40% of cases. Treatment strategies for biphasic mesothelioma often try to leverage the responsiveness of the epithelioid component while acknowledging the aggressive nature of the sarcomatoid cells, making treatment planning a delicate balancing act.
Patient Age and Overall Health (Performance Status)
Beyond the disease itself, the characteristics of the individual patient play a profound role in determining prognosis. Specifically, a patient's age and their overall health, often quantified by what physicians call "performance status," are incredibly important in shaping treatment decisions and predicting outcomes. It makes intuitive sense, doesn't it? A younger, healthier individual is generally better equipped to withstand the rigors of aggressive cancer treatment.
Let's talk about age first. Mesothelioma is predominantly a disease of older adults, given its long latency period. The average age at diagnosis is often in the late 60s or early 70s. Younger patients – those diagnosed in their 40s, 50s, or even early 60s – tend to have a more favorable prognosis. Why? Several reasons. Firstly, their bodies are generally stronger, with better organ function, making them more tolerant of intensive treatments like aggressive surgery, high-dose chemotherapy, and radiation. They recover faster from procedures, experience fewer severe side effects, and are more likely to complete a full course of planned therapy. Secondly, younger patients often have fewer co-morbidities (other health conditions like heart disease, diabetes, or kidney issues) that could complicate treatment or recovery. While age is just a number, it's also a strong indicator of physiological reserve.
Then there's overall health, which is often assessed using a tool called the performance status scale. The most common ones are the Eastern Cooperative Oncology Group (ECOG) Performance Status or the Karnofsky Performance Status. These scales essentially measure a patient's ability to perform daily activities and care for themselves.
- ECOG 0: Fully active, able to carry on all pre-disease performance without restriction.
- ECOG 1: Restricted in physically strenuous activity but ambulatory and able to carry out light work.
- ECOG 2: Ambulatory and capable of self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.
- ECOG 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours.
- ECOG 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.
Gender and Other Biological Markers
It might seem surprising, but even something as fundamental as gender can play a subtle role in mesothelioma prognosis. Historically, men have been diagnosed with mesothelioma at a much higher rate than women, largely due to occupational exposure in industries predominantly staffed by men (e.g., construction, shipbuilding, military). However, studies have consistently shown that women diagnosed with mesothelioma tend to have a slightly, though statistically significant, better prognosis than men. The reasons for this aren't entirely clear, but hypotheses include potential hormonal differences, variations in immune response, or even the possibility that women might be diagnosed at slightly earlier stages due to less severe exposure levels or different symptom presentation. Whatever the reason, it's a consistent observation in the data.
Beyond gender, the field of mesothelioma research is rapidly advancing, with increasing focus on emerging genetic and molecular biomarkers. These are specific characteristics within the tumor cells or in the patient's blood that can provide valuable prognostic information and, crucially, guide targeted therapies.
For instance, researchers are looking at:
- Genetic Mutations: Specific mutations within the tumor's DNA can indicate how aggressive the cancer might be or how it might respond to certain drugs. For example, mutations in genes like BAP1 (BRCA1 Associated Protein 1) are frequently found in mesothelioma cells. While a BAP1 mutation can sometimes indicate a better response to certain treatments, its full prognostic implications are still being actively researched.
- Protein Expression: The presence or absence of certain proteins on the surface of mesothelioma cells can be indicative. For example, high expression of PD-L1 (Programmed Death-Ligand 1) might suggest a better response to immunotherapy drugs, which are designed to unleash the body's immune system against cancer.
- Circulating Tumor DNA (ctDNA): This involves detecting fragments of tumor DNA in a patient's blood. The amount and type of ctDNA can potentially indicate tumor burden, treatment response, and disease progression, offering a less invasive way to monitor prognosis.
- Immunohistochemical Markers: Pathologists use specific stains to identify proteins in tumor tissue that help confirm the diagnosis of mesothelioma and differentiate it from other cancers. Some of these markers can also provide prognostic information.
Location of the Tumor and Spread (Metastasis)
The specific location of the primary tumor and the extent to which it has spread, or metastasized, are profoundly influential factors in determining a mesothelioma patient's prognosis. This isn't just about "stage"; it's about the physical reality of the tumor's presence and its impact on vital organs.
Let's break it down:
- Primary Site (Pleural vs. Peritoneal): As we touched upon earlier, the primary location of the mesothelioma matters. Peritoneal mesothelioma, the type found in the abdomen, often has a slightly better prognosis than pleural mesothelioma, the type in the chest. This is largely because peritoneal mesothelioma, while aggressive, can sometimes be contained within the abdominal cavity for longer periods. It is also often more amenable to a highly aggressive treatment approach involving cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC), which directly bathes the abdominal cavity with heated chemotherapy. This combination has shown impressive results in carefully selected peritoneal patients, leading to significantly extended survival times, sometimes many years. Pleural mesothelioma, while also treated aggressively, often presents more challenges for complete resection due to the intricate anatomy of the chest cavity and its proximity to vital structures like the heart and major blood vessels.
- Tumor Size and Resectability: The sheer size of the primary tumor is a major prognostic indicator. Smaller, more localized tumors are inherently easier to surgically remove – a concept known as "resectability." If a tumor can be completely removed (a "R0 resection" where no visible cancer remains), the prognosis is significantly better. Large tumors, or those that have extensively infiltrated surrounding tissues, often become unresectable. This means surgery is either impossible or would cause too much damage, leaving residual disease and a much poorer outlook. Surgeons specializing in mesothelioma have developed advanced techniques to achieve maximum resection, but there are always limits dictated by the tumor's extent.
- Extent of Local Spread and Invasion: Mesothelioma, by its nature, tends to spread along surfaces rather than forming a distinct, confined mass. This means it can "seed" the lining of the chest or abdomen, creating multiple small tumors. When it invades adjacent structures – for pleural mesothelioma, this could be the chest wall, diaphragm, pericardium, or even the lung itself; for peritoneal, it could be the bowel, liver capsule, or bladder – the prognosis worsens dramatically. Invasion indicates a more aggressive biological behavior and makes complete surgical removal increasingly difficult. The more structures involved, the more challenging the fight.
- Distant Metastasis: This is the grim reality of Stage 4 disease. When mesothelioma cells break away from the primary tumor and travel through the bloodstream or lymphatic system to form new tumors in distant organs (like the brain, bones, liver, or adrenal glands), the disease is considered systemic. At this point, the focus shifts almost entirely from curative intent to palliative care, aimed at controlling the cancer's spread, managing symptoms, and preserving quality of life. The presence of distant metastases is a strong indicator of a very poor prognosis, as it signifies that the cancer has overwhelmed the body's defenses and is widely disseminated.
*
Pro-Tip: Seek a Mesothelioma Specialist
Given the rarity and complexity of mesothelioma, it is absolutely paramount to seek treatment from a medical center and specialists who have extensive experience with this specific cancer. General oncologists, while highly skilled, may not have the deep expertise in the nuances of mesothelioma staging, histology, and the aggressive, multimodal treatments required. A specialist will be better equipped to accurately assess your tumor's location and spread, recommend the most advanced surgical techniques (if applicable), and offer access to cutting-edge clinical trials. Even if it means traveling outside of Wilmington, this step can profoundly impact your prognosis.
*
Mesothelioma Treatment Options and Their Influence on Prognosis
Understanding the factors that shape prognosis is one thing, but knowing the treatment options available – and how they, in turn, influence that prognosis – is another entirely. This is where hope meets harsh reality, where cutting-edge medicine battles a formidable foe. For mesothelioma, effective treatment is rarely a single modality; it's almost always a carefully orchestrated, aggressive, and individualized combination of therapies.
Standard Treatment Modalities: Surgery, Chemotherapy, and Radiation
When it comes to the conventional arsenal against mesothelioma, the "big three" are surgery, chemotherapy, and radiation. For most eligible patients, the best outcomes are achieved when these modalities are combined in a strategic, multimodal approach. This isn't a pick-and-choose menu; it's more like a symphony where each instrument plays a vital role.
Surgery is often considered the cornerstone of treatment for early to moderately advanced mesothelioma, particularly for epithelioid cell types. The goal of surgery is to remove as much of the visible tumor as possible, a process known as cytoreduction. For pleural mesothelioma, this can involve highly invasive procedures like extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D), which we’ll discuss in more detail shortly. For peritoneal mesothelioma, cytoreductive surgery combined with heated intraperitoneal chemotherapy (HIPEC) is the gold standard. The impact of successful surgery on prognosis is significant, as physically removing the bulk of the cancer can dramatically reduce tumor burden and extend life, especially when followed by systemic therapies to target any remaining microscopic disease. However, surgery is only an option for patients who are healthy enough to withstand these major operations and whose disease is not too widespread.
Chemotherapy is almost universally used in mesothelioma treatment, either before surgery (neoadjuvant), after surgery (adjuvant), or as the primary treatment for advanced or unresectable disease. The standard chemotherapy regimen often involves a combination of platinum-based drugs (like cisplatin or carboplatin) and pemetrexed (Alimta). These drugs work by killing rapidly dividing cells, including cancer cells. While chemotherapy rarely cures mesothelioma on its own, it plays a crucial role in shrinking tumors, controlling disease progression, alleviating symptoms, and extending survival. For many patients, chemotherapy is the frontline defense, and its effectiveness in slowing the disease's progression directly impacts the length and quality of their remaining life.
Radiation therapy uses high-energy X-rays or other particles to kill cancer cells or keep them from growing. It can be used in several ways for mesothelioma:
- Adjuvant Radiation: After surgery, to kill any remaining microscopic cancer cells in the surgical bed and reduce the risk of local recurrence.
- Palliative Radiation: To relieve symptoms caused by
